1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Drugs In Development, 2022, provides an overview of the Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Chronic myeloid leukemia (CML), also known as chronic myelogenous leukemia, is a type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood. Risk factors for CML include high-dose radiation, age and gender. Symptoms include weakness, fatigue, night sweats, weight loss, fever, bone pain, an enlarged spleen and pain or a sense of fullness in the belly. Treatment includes radiation therapy, blood cell transplantation and chemotherapy.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 4, 28, 22, 1, 2, 19, 5 and 2 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 8, 3, 4 and 4 molecules, respectively.
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology).
- The pipeline guide reviews pipeline therapeutics for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Overview
- Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Companies Involved in Therapeutics Development
- Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Drug Profiles
- Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Dormant Projects
- Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Discontinued Products
- Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Product Development Milestones
- Featured News & Press Releases
- Sep 21, 2022: Ascentage Pharma announces phase I/II data of olverembatinib (HQP1351) published in the Journal of Hematology & Oncology, further validating the drug's best-in-class potential
- Aug 31, 2022: Scemblix, a first-in-class CML treatment with new mechanism of action approved in Canada
- Aug 29, 2022: Novartis Scemblix, with novel mechanism of action, approved by the European Commission for adult patients with chronic myeloid leukemia
- Aug 26, 2022: Inhibikase Therapeutics announces FDA clearance of Investigational New Drug Application for IkT-001Pro for the Treatment of Chronic Myelogenous Leukemia
- Jul 22, 2022: Ascentage Pharma and Tanner Pharma Group initiate a global innovative Named Patient Program
- Jul 21, 2022: Ascentage Pharma announces clinical trial application for Olverembatinib (HQP1351) approved in Canada
- Jul 19, 2022: The National Medical Products Adminstration accepted and granted priortiy review designation to a new drug application for olverembatinib for the treatment of drug-resistant chornic myeloid leukemia
- Jun 30, 2022: First STAMP (specifically targeting the abl myristoyl pocket) inhibitor for treatment for chronic myeloid leukaemia (CML), Scemblix (asciminib) receives NICE final draft recommendation in Great Britain
- Jun 24, 2022: Novartis receives positive CHMP opinion for Scemblix, a novel treatment for adult patients with chronic myeloid leukemia
- Jun 07, 2022: Novartis Scemblix, with novel mechanism of action, shows superior, long-term efficacy and consistent tolerability in 96-week follow-up of chronic myeloid leukemia trial
- Jan 05, 2022: The first commercial insurance landed in Huzhou, and Ascentage Pharma's Nerike was included in the "Zheli Medical Insurance South Taihu Health Insurance"
- Dec 14, 2021: ASH 2021 - Ascentage Pharma releases long-term clinical data of olverembatinib (HQP1351) in oral presentation demonstrating efficacy and safety
- Dec 11, 2021: Novartis Scemblix demonstrates sustained response rate in 48-week follow-up in patients with chronic myeloid leukemia
- Nov 25, 2021: Ascentage Pharma announces approval by NMPA for China’s first approved third-generation BCR-ABL TKI HQP1351 (Olverembatinib)
- Nov 22, 2021: Ascentage Pharma's olverembatinib granted orphan designation by the European Commission for the treatment of chronic myeloid leukemia
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Dormant Projects, 2022
- Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Discontinued Products, 2022
- Number of Products under Development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- A. Menarini Industrie Farmaceutiche Riunite Srl
- AbbVie Inc
- Actinium Pharmaceuticals Inc
- Arromax Pharmatech Co Ltd
- Ascentage Pharma Group International
- Astex Pharmaceuticals Inc
- Aurigene Discovery Technologies Ltd
- Autolus Therapeutics Plc
- Bio-Path Holdings Inc
- BioLineRx Ltd
- Bristol-Myers Squibb Co
- Celularity Inc
- Chimeric Therapeutics Ltd
- CSPC Pharmaceutical Group Ltd
- Enliven Therapeutics Inc
- Escend Pharmaceuticals Inc
- Eureka Therapeutics Inc
- ExCellThera Inc
- F. Hoffmann-La Roche Ltd
- Fate Therapeutics Inc
- Fusion Pharmaceuticals US Inc
- Gamida Cell Ltd
- GT Biopharma Inc
- Handa Pharmaceuticals LLC
- HEC Pharma Co Ltd
- Helocyte Biosciences Inc
- HighPass Bio Inc
- Housey Pharmaceutical Research Laboratories LLC
- iCell Gene Therapeutics LLC
- Ilyang Pharmaceutical Co Ltd
- ImmunityBio Inc
- ImmunoForge Co Ltd
- ImmunoGen Inc
- IN8bio Inc
- Inhibikase Therapeutics Inc
- InnoCure Therapeutics Inc
- Johnson & Johnson
- Kartos Therapeutics Inc
- Kiadis Pharma NV
- MAA Laboratories Inc
- MacroGenics Inc
- Mana Therapeutics Inc
- MedPacto Inc
- Millennium Pharmaceuticals Inc
- Nanjing Sanhome Pharmaceutical Co Ltd
- Nanocopoeia LLC
- Nemucore Medical Innovations Inc
- Nohla Therapeutics Inc
- Novartis AG
- Novelty Nobility Inc
- Ono Pharmaceutical Co Ltd
- Otsuka Pharmaceutical Co Ltd
- Pfizer Inc
- Pharma Mar SA
- PharmaEssentia Corp
- PRISM Pharma Co Ltd
- PYC Therapeutics Ltd
- Sanofi
- Shenogen Pharma Group Ltd
- Shenzhen Targetrx Inc
- Sun Pharma Advanced Research Company Ltd
- Synactix Pharmaceuticals Inc
- Takeda Pharmaceutical Co Ltd
- Telix Pharmaceuticals Ltd
- Terns Pharmaceuticals Inc
- TotalClarity Inc
- Vincerx Pharma Inc
- VioQuest Pharmaceuticals Inc (Inactive)
- Xencor Inc
- Xspray Pharma AB
